SrasV1, PascalFrancis, Corpus, bibRecord, 000843

Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus

Identifieur interne : 000843 ( PascalFrancis/Corpus ); précédent : 000842; suivant : 000844

Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus

Auteurs : Jody D. Berry ; Steven Jones ; Michael A. Drebot ; Anton Andonov ; Marta Sabara ; Xin Y. Yuan ; Hana Weingartl ; Lisa Fernando ; Peter Marszal ; Jason Gren ; Brigitte Nicolas ; Maya Andonova ; Francesca Ranada ; Michael J. Gubbins ; T. Blake Ball ; Paul Kitching ; Yan Li ; Amin Kabani ; Frank Plummer

Source :

Journal of virological methods [ 0166-0934 ] ; 2004.

RBID : Pascal:04-0407064

Descripteurs français

Pascal (Inist)
- Coronavirus, Développement, Anticorps monoclonal, Déterminant antigénique, Immunochimie, Microbiologie, Méthode, Virologie, Syndrome respiratoire aigu sévère.

English descriptors

KwdEn :
- Antigenic determinant, Coronavirus, Development, Immunochemistry, Method, Microbiology, Monoclonal antibody, Severe acute respiratory syndrome, Virology.

Abstract

There is a global need to elucidate protective antigens expressed by the SARS-coronavirus (SARS-CoV). Monoclonal antibody reagents that recognise specific antigens on SARS-CoV are needed urgently. In this report, the development and immunochemical characterisation of a panel of murine monoclonal antibodies (mAbs) against the SARS-CoV is presented, based upon their specificity, binding requirements, and biological activity. Initial screening by ELISA, using highly purified virus as the coating antigen, resulted in the selection of 103 mAbs to the SARS virus. Subsequent screening steps reduced this panel to seventeen IgG mAbs. A single mAb, F26G15, is specific for the nucleoprotein as seen in Western immunoblot while five other mAbs react with the Spike protein. Two of these Spike-specific mAbs demonstrate the ability to neutralise SARS-CoV in vitro while another four Western immunoblot-negative mAbs also neutralise the virus. The utility of these mAbs for diagnostic development is demonstrated. Antibody from convalescent SARS patients, but not normal human serum, is also shown to specifically compete off binding of mAbs to whole SARS-CoV. These studies highlight the importance of using standardised assays and reagents. These mAbs will be useful for the development of diagnostic tests, studies of SARS-CoV pathogenesis and vaccine development.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0166-0934`
A02	`01`			`@0 JVMEDH`
A03		`1`		`@0 J. virol. methods`
A05				`@2 120`
A06				`@2 1`
A08	`01`	`1`	`ENG`	`@1 Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus`
A11	`01`	`1`		`@1 BERRY (Jody D.)`
A11	`02`	`1`		`@1 JONES (Steven)`
A11	`03`	`1`		`@1 DREBOT (Michael A.)`
A11	`04`	`1`		`@1 ANDONOV (Anton)`
A11	`05`	`1`		`@1 SABARA (Marta)`
A11	`06`	`1`		`@1 YUAN (Xin Y.)`
A11	`07`	`1`		`@1 WEINGARTL (Hana)`
A11	`08`	`1`		`@1 FERNANDO (Lisa)`
A11	`09`	`1`		`@1 MARSZAL (Peter)`
A11	`10`	`1`		`@1 GREN (Jason)`
A11	`11`	`1`		`@1 NICOLAS (Brigitte)`
A11	`12`	`1`		`@1 ANDONOVA (Maya)`
A11	`13`	`1`		`@1 RANADA (Francesca)`
A11	`14`	`1`		`@1 GUBBINS (Michael J.)`
A11	`15`	`1`		`@1 BALL (T. Blake)`
A11	`16`	`1`		`@1 KITCHING (Paul)`
A11	`17`	`1`		`@1 LI (Yan)`
A11	`18`	`1`		`@1 KABANI (Amin)`
A11	`19`	`1`		`@1 PLUMMER (Frank)`
A14	`01`			`@1 National Centre for Foreign Animal Disease, CFIA @2 Winnipeg @3 CAN @Z 1 aut. @Z 5 aut. @Z 6 aut. @Z 7 aut. @Z 9 aut. @Z 10 aut. @Z 11 aut. @Z 13 aut. @Z 16 aut.`
A14	`02`			`@1 Department of Medical Microbiology, University of Manitoba @2 Winnipeg @3 CAN @Z 1 aut. @Z 3 aut. @Z 4 aut. @Z 15 aut. @Z 18 aut. @Z 19 aut.`
A14	`03`			`@1 National Microbiology Laboratory Health Canada @2 Winnipeg @3 CAN @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 6 aut. @Z 8 aut. @Z 11 aut. @Z 12 aut. @Z 13 aut. @Z 14 aut. @Z 17 aut. @Z 18 aut. @Z 19 aut.`
A14	`04`			`@1 Department of Immunology, University of Manitoba @2 Winnipeg @3 CAN @Z 2 aut.`
A20				`@1 87-96`
A21				`@1 2004`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 18295 @5 354000120108570110`
A44				`@0 0000 @1 © 2004 INIST-CNRS. All rights reserved.`
A45				`@0 22 ref.`
A47	`01`	`1`		`@0 04-0407064`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Journal of virological methods`
A66	`01`			`@0 NLD`
C01	`01`		`ENG`	@0 There is a global need to elucidate protective antigens expressed by the SARS-coronavirus (SARS-CoV). Monoclonal antibody reagents that recognise specific antigens on SARS-CoV are needed urgently. In this report, the development and immunochemical characterisation of a panel of murine monoclonal antibodies (mAbs) against the SARS-CoV is presented, based upon their specificity, binding requirements, and biological activity. Initial screening by ELISA, using highly purified virus as the coating antigen, resulted in the selection of 103 mAbs to the SARS virus. Subsequent screening steps reduced this panel to seventeen IgG mAbs. A single mAb, F26G15, is specific for the nucleoprotein as seen in Western immunoblot while five other mAbs react with the Spike protein. Two of these Spike-specific mAbs demonstrate the ability to neutralise SARS-CoV in vitro while another four Western immunoblot-negative mAbs also neutralise the virus. The utility of these mAbs for diagnostic development is demonstrated. Antibody from convalescent SARS patients, but not normal human serum, is also shown to specifically compete off binding of mAbs to whole SARS-CoV. These studies highlight the importance of using standardised assays and reagents. These mAbs will be useful for the development of diagnostic tests, studies of SARS-CoV pathogenesis and vaccine development.
C02	`01`	`X`		`@0 002A05C09`
C03	`01`	`X`	`FRE`	`@0 Coronavirus @2 NW @5 01`
C03	`01`	`X`	`ENG`	`@0 Coronavirus @2 NW @5 01`
C03	`01`	`X`	`SPA`	`@0 Coronavirus @2 NW @5 01`
C03	`02`	`X`	`FRE`	`@0 Développement @5 05`
C03	`02`	`X`	`ENG`	`@0 Development @5 05`
C03	`02`	`X`	`SPA`	`@0 Desarrollo @5 05`
C03	`03`	`X`	`FRE`	`@0 Anticorps monoclonal @5 06`
C03	`03`	`X`	`ENG`	`@0 Monoclonal antibody @5 06`
C03	`03`	`X`	`SPA`	`@0 Anticuerpo monoclonal @5 06`
C03	`04`	`X`	`FRE`	`@0 Déterminant antigénique @5 07`
C03	`04`	`X`	`ENG`	`@0 Antigenic determinant @5 07`
C03	`04`	`X`	`SPA`	`@0 Determinante antigénico @5 07`
C03	`05`	`X`	`FRE`	`@0 Immunochimie @5 08`
C03	`05`	`X`	`ENG`	`@0 Immunochemistry @5 08`
C03	`05`	`X`	`SPA`	`@0 Inmunoquímica @5 08`
C03	`06`	`X`	`FRE`	`@0 Microbiologie @5 09`
C03	`06`	`X`	`ENG`	`@0 Microbiology @5 09`
C03	`06`	`X`	`SPA`	`@0 Microbiología @5 09`
C03	`07`	`X`	`FRE`	`@0 Méthode @5 10`
C03	`07`	`X`	`ENG`	`@0 Method @5 10`
C03	`07`	`X`	`SPA`	`@0 Método @5 10`
C03	`08`	`X`	`FRE`	`@0 Virologie @5 11`
C03	`08`	`X`	`ENG`	`@0 Virology @5 11`
C03	`08`	`X`	`SPA`	`@0 Virología @5 11`
C03	`09`	`X`	`FRE`	`@0 Syndrome respiratoire aigu sévère @2 NM @5 14`
C03	`09`	`X`	`ENG`	`@0 Severe acute respiratory syndrome @2 NM @5 14`
C03	`09`	`X`	`SPA`	`@0 Síndrome respiratorio agudo severo @2 NM @5 14`
C07	`01`	`X`	`FRE`	`@0 Coronaviridae @2 NW`
C07	`01`	`X`	`ENG`	`@0 Coronaviridae @2 NW`
C07	`01`	`X`	`SPA`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`FRE`	`@0 Nidovirales @2 NW`
C07	`02`	`X`	`ENG`	`@0 Nidovirales @2 NW`
C07	`02`	`X`	`SPA`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`03`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`03`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`04`	`X`	`FRE`	`@0 Virose @2 NM`
C07	`04`	`X`	`ENG`	`@0 Viral disease @2 NM`
C07	`04`	`X`	`SPA`	`@0 Virosis @2 NM`
C07	`05`	`X`	`FRE`	`@0 Infection @2 NM`
C07	`05`	`X`	`ENG`	`@0 Infection @2 NM`
C07	`05`	`X`	`SPA`	`@0 Infección @2 NM`
N21				`@1 229`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 04-0407064 INIST
ET :	Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus
AU :	BERRY (Jody D.); JONES (Steven); DREBOT (Michael A.); ANDONOV (Anton); SABARA (Marta); YUAN (Xin Y.); WEINGARTL (Hana); FERNANDO (Lisa); MARSZAL (Peter); GREN (Jason); NICOLAS (Brigitte); ANDONOVA (Maya); RANADA (Francesca); GUBBINS (Michael J.); BALL (T. Blake); KITCHING (Paul); LI (Yan); KABANI (Amin); PLUMMER (Frank)
AF :	National Centre for Foreign Animal Disease, CFIA/Winnipeg/Canada (1 aut., 5 aut., 6 aut., 7 aut., 9 aut., 10 aut., 11 aut., 13 aut., 16 aut.); Department of Medical Microbiology, University of Manitoba/Winnipeg/Canada (1 aut., 3 aut., 4 aut., 15 aut., 18 aut., 19 aut.); National Microbiology Laboratory Health Canada/Winnipeg/Canada (2 aut., 3 aut., 4 aut., 6 aut., 8 aut., 11 aut., 12 aut., 13 aut., 14 aut., 17 aut., 18 aut., 19 aut.); Department of Immunology, University of Manitoba/Winnipeg/Canada (2 aut.)
DT :	Publication en série; Niveau analytique
SO :	Journal of virological methods; ISSN 0166-0934; Coden JVMEDH; Pays-Bas; Da. 2004; Vol. 120; No. 1; Pp. 87-96; Bibl. 22 ref.
LA :	Anglais
EA :	There is a global need to elucidate protective antigens expressed by the SARS-coronavirus (SARS-CoV). Monoclonal antibody reagents that recognise specific antigens on SARS-CoV are needed urgently. In this report, the development and immunochemical characterisation of a panel of murine monoclonal antibodies (mAbs) against the SARS-CoV is presented, based upon their specificity, binding requirements, and biological activity. Initial screening by ELISA, using highly purified virus as the coating antigen, resulted in the selection of 103 mAbs to the SARS virus. Subsequent screening steps reduced this panel to seventeen IgG mAbs. A single mAb, F26G15, is specific for the nucleoprotein as seen in Western immunoblot while five other mAbs react with the Spike protein. Two of these Spike-specific mAbs demonstrate the ability to neutralise SARS-CoV in vitro while another four Western immunoblot-negative mAbs also neutralise the virus. The utility of these mAbs for diagnostic development is demonstrated. Antibody from convalescent SARS patients, but not normal human serum, is also shown to specifically compete off binding of mAbs to whole SARS-CoV. These studies highlight the importance of using standardised assays and reagents. These mAbs will be useful for the development of diagnostic tests, studies of SARS-CoV pathogenesis and vaccine development.
CC :	002A05C09
FD :	Coronavirus; Développement; Anticorps monoclonal; Déterminant antigénique; Immunochimie; Microbiologie; Méthode; Virologie; Syndrome respiratoire aigu sévère
FG :	Coronaviridae; Nidovirales; Virus; Virose; Infection
ED :	Coronavirus; Development; Monoclonal antibody; Antigenic determinant; Immunochemistry; Microbiology; Method; Virology; Severe acute respiratory syndrome
EG :	Coronaviridae; Nidovirales; Virus; Viral disease; Infection
SD :	Coronavirus; Desarrollo; Anticuerpo monoclonal; Determinante antigénico; Inmunoquímica; Microbiología; Método; Virología; Síndrome respiratorio agudo severo
LO :	INIST-18295.354000120108570110
ID :	04-0407064

Links to Exploration step

Pascal:04-0407064

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus</title>
<author><name sortKey="Berry, Jody D" sort="Berry, Jody D" uniqKey="Berry J" first="Jody D." last="Berry">Jody D. Berry</name>
<affiliation><inist:fA14 i1="01"><s1>National Centre for Foreign Animal Disease, CFIA</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Medical Microbiology, University of Manitoba</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jones, Steven" sort="Jones, Steven" uniqKey="Jones S" first="Steven" last="Jones">Steven Jones</name>
<affiliation><inist:fA14 i1="03"><s1>National Microbiology Laboratory Health Canada</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>17 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Department of Immunology, University of Manitoba</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Drebot, Michael A" sort="Drebot, Michael A" uniqKey="Drebot M" first="Michael A." last="Drebot">Michael A. Drebot</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Medical Microbiology, University of Manitoba</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>National Microbiology Laboratory Health Canada</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>17 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Andonov, Anton" sort="Andonov, Anton" uniqKey="Andonov A" first="Anton" last="Andonov">Anton Andonov</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Medical Microbiology, University of Manitoba</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>National Microbiology Laboratory Health Canada</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>17 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sabara, Marta" sort="Sabara, Marta" uniqKey="Sabara M" first="Marta" last="Sabara">Marta Sabara</name>
<affiliation><inist:fA14 i1="01"><s1>National Centre for Foreign Animal Disease, CFIA</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yuan, Xin Y" sort="Yuan, Xin Y" uniqKey="Yuan X" first="Xin Y." last="Yuan">Xin Y. Yuan</name>
<affiliation><inist:fA14 i1="01"><s1>National Centre for Foreign Animal Disease, CFIA</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>National Microbiology Laboratory Health Canada</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>17 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Weingartl, Hana" sort="Weingartl, Hana" uniqKey="Weingartl H" first="Hana" last="Weingartl">Hana Weingartl</name>
<affiliation><inist:fA14 i1="01"><s1>National Centre for Foreign Animal Disease, CFIA</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fernando, Lisa" sort="Fernando, Lisa" uniqKey="Fernando L" first="Lisa" last="Fernando">Lisa Fernando</name>
<affiliation><inist:fA14 i1="03"><s1>National Microbiology Laboratory Health Canada</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>17 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marszal, Peter" sort="Marszal, Peter" uniqKey="Marszal P" first="Peter" last="Marszal">Peter Marszal</name>
<affiliation><inist:fA14 i1="01"><s1>National Centre for Foreign Animal Disease, CFIA</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gren, Jason" sort="Gren, Jason" uniqKey="Gren J" first="Jason" last="Gren">Jason Gren</name>
<affiliation><inist:fA14 i1="01"><s1>National Centre for Foreign Animal Disease, CFIA</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Nicolas, Brigitte" sort="Nicolas, Brigitte" uniqKey="Nicolas B" first="Brigitte" last="Nicolas">Brigitte Nicolas</name>
<affiliation><inist:fA14 i1="01"><s1>National Centre for Foreign Animal Disease, CFIA</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>National Microbiology Laboratory Health Canada</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>17 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Andonova, Maya" sort="Andonova, Maya" uniqKey="Andonova M" first="Maya" last="Andonova">Maya Andonova</name>
<affiliation><inist:fA14 i1="03"><s1>National Microbiology Laboratory Health Canada</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>17 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ranada, Francesca" sort="Ranada, Francesca" uniqKey="Ranada F" first="Francesca" last="Ranada">Francesca Ranada</name>
<affiliation><inist:fA14 i1="01"><s1>National Centre for Foreign Animal Disease, CFIA</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>National Microbiology Laboratory Health Canada</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>17 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gubbins, Michael J" sort="Gubbins, Michael J" uniqKey="Gubbins M" first="Michael J." last="Gubbins">Michael J. Gubbins</name>
<affiliation><inist:fA14 i1="03"><s1>National Microbiology Laboratory Health Canada</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>17 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ball, T Blake" sort="Ball, T Blake" uniqKey="Ball T" first="T. Blake" last="Ball">T. Blake Ball</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Medical Microbiology, University of Manitoba</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kitching, Paul" sort="Kitching, Paul" uniqKey="Kitching P" first="Paul" last="Kitching">Paul Kitching</name>
<affiliation><inist:fA14 i1="01"><s1>National Centre for Foreign Animal Disease, CFIA</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Li, Yan" sort="Li, Yan" uniqKey="Li Y" first="Yan" last="Li">Yan Li</name>
<affiliation><inist:fA14 i1="03"><s1>National Microbiology Laboratory Health Canada</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>17 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kabani, Amin" sort="Kabani, Amin" uniqKey="Kabani A" first="Amin" last="Kabani">Amin Kabani</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Medical Microbiology, University of Manitoba</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>National Microbiology Laboratory Health Canada</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>17 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Plummer, Frank" sort="Plummer, Frank" uniqKey="Plummer F" first="Frank" last="Plummer">Frank Plummer</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Medical Microbiology, University of Manitoba</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>National Microbiology Laboratory Health Canada</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>17 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0407064</idno>
<date when="2004">2004</date>
<idno type="stanalyst">PASCAL 04-0407064 INIST</idno>
<idno type="RBID">Pascal:04-0407064</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000843</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus</title>
<author><name sortKey="Berry, Jody D" sort="Berry, Jody D" uniqKey="Berry J" first="Jody D." last="Berry">Jody D. Berry</name>
<affiliation><inist:fA14 i1="01"><s1>National Centre for Foreign Animal Disease, CFIA</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Medical Microbiology, University of Manitoba</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jones, Steven" sort="Jones, Steven" uniqKey="Jones S" first="Steven" last="Jones">Steven Jones</name>
<affiliation><inist:fA14 i1="03"><s1>National Microbiology Laboratory Health Canada</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>17 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Department of Immunology, University of Manitoba</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Drebot, Michael A" sort="Drebot, Michael A" uniqKey="Drebot M" first="Michael A." last="Drebot">Michael A. Drebot</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Medical Microbiology, University of Manitoba</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>National Microbiology Laboratory Health Canada</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>17 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Andonov, Anton" sort="Andonov, Anton" uniqKey="Andonov A" first="Anton" last="Andonov">Anton Andonov</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Medical Microbiology, University of Manitoba</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>National Microbiology Laboratory Health Canada</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>17 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sabara, Marta" sort="Sabara, Marta" uniqKey="Sabara M" first="Marta" last="Sabara">Marta Sabara</name>
<affiliation><inist:fA14 i1="01"><s1>National Centre for Foreign Animal Disease, CFIA</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yuan, Xin Y" sort="Yuan, Xin Y" uniqKey="Yuan X" first="Xin Y." last="Yuan">Xin Y. Yuan</name>
<affiliation><inist:fA14 i1="01"><s1>National Centre for Foreign Animal Disease, CFIA</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>National Microbiology Laboratory Health Canada</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>17 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Weingartl, Hana" sort="Weingartl, Hana" uniqKey="Weingartl H" first="Hana" last="Weingartl">Hana Weingartl</name>
<affiliation><inist:fA14 i1="01"><s1>National Centre for Foreign Animal Disease, CFIA</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fernando, Lisa" sort="Fernando, Lisa" uniqKey="Fernando L" first="Lisa" last="Fernando">Lisa Fernando</name>
<affiliation><inist:fA14 i1="03"><s1>National Microbiology Laboratory Health Canada</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>17 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marszal, Peter" sort="Marszal, Peter" uniqKey="Marszal P" first="Peter" last="Marszal">Peter Marszal</name>
<affiliation><inist:fA14 i1="01"><s1>National Centre for Foreign Animal Disease, CFIA</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gren, Jason" sort="Gren, Jason" uniqKey="Gren J" first="Jason" last="Gren">Jason Gren</name>
<affiliation><inist:fA14 i1="01"><s1>National Centre for Foreign Animal Disease, CFIA</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Nicolas, Brigitte" sort="Nicolas, Brigitte" uniqKey="Nicolas B" first="Brigitte" last="Nicolas">Brigitte Nicolas</name>
<affiliation><inist:fA14 i1="01"><s1>National Centre for Foreign Animal Disease, CFIA</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>National Microbiology Laboratory Health Canada</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>17 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Andonova, Maya" sort="Andonova, Maya" uniqKey="Andonova M" first="Maya" last="Andonova">Maya Andonova</name>
<affiliation><inist:fA14 i1="03"><s1>National Microbiology Laboratory Health Canada</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>17 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ranada, Francesca" sort="Ranada, Francesca" uniqKey="Ranada F" first="Francesca" last="Ranada">Francesca Ranada</name>
<affiliation><inist:fA14 i1="01"><s1>National Centre for Foreign Animal Disease, CFIA</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>National Microbiology Laboratory Health Canada</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>17 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gubbins, Michael J" sort="Gubbins, Michael J" uniqKey="Gubbins M" first="Michael J." last="Gubbins">Michael J. Gubbins</name>
<affiliation><inist:fA14 i1="03"><s1>National Microbiology Laboratory Health Canada</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>17 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ball, T Blake" sort="Ball, T Blake" uniqKey="Ball T" first="T. Blake" last="Ball">T. Blake Ball</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Medical Microbiology, University of Manitoba</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kitching, Paul" sort="Kitching, Paul" uniqKey="Kitching P" first="Paul" last="Kitching">Paul Kitching</name>
<affiliation><inist:fA14 i1="01"><s1>National Centre for Foreign Animal Disease, CFIA</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Li, Yan" sort="Li, Yan" uniqKey="Li Y" first="Yan" last="Li">Yan Li</name>
<affiliation><inist:fA14 i1="03"><s1>National Microbiology Laboratory Health Canada</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>17 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kabani, Amin" sort="Kabani, Amin" uniqKey="Kabani A" first="Amin" last="Kabani">Amin Kabani</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Medical Microbiology, University of Manitoba</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>National Microbiology Laboratory Health Canada</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>17 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Plummer, Frank" sort="Plummer, Frank" uniqKey="Plummer F" first="Frank" last="Plummer">Frank Plummer</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Medical Microbiology, University of Manitoba</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>National Microbiology Laboratory Health Canada</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>17 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of virological methods</title>
<title level="j" type="abbreviated">J. virol. methods</title>
<idno type="ISSN">0166-0934</idno>
<imprint><date when="2004">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of virological methods</title>
<title level="j" type="abbreviated">J. virol. methods</title>
<idno type="ISSN">0166-0934</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antigenic determinant</term>
<term>Coronavirus</term>
<term>Development</term>
<term>Immunochemistry</term>
<term>Method</term>
<term>Microbiology</term>
<term>Monoclonal antibody</term>
<term>Severe acute respiratory syndrome</term>
<term>Virology</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Coronavirus</term>
<term>Développement</term>
<term>Anticorps monoclonal</term>
<term>Déterminant antigénique</term>
<term>Immunochimie</term>
<term>Microbiologie</term>
<term>Méthode</term>
<term>Virologie</term>
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">There is a global need to elucidate protective antigens expressed by the SARS-coronavirus (SARS-CoV). Monoclonal antibody reagents that recognise specific antigens on SARS-CoV are needed urgently. In this report, the development and immunochemical characterisation of a panel of murine monoclonal antibodies (mAbs) against the SARS-CoV is presented, based upon their specificity, binding requirements, and biological activity. Initial screening by ELISA, using highly purified virus as the coating antigen, resulted in the selection of 103 mAbs to the SARS virus. Subsequent screening steps reduced this panel to seventeen IgG mAbs. A single mAb, F26G15, is specific for the nucleoprotein as seen in Western immunoblot while five other mAbs react with the Spike protein. Two of these Spike-specific mAbs demonstrate the ability to neutralise SARS-CoV in vitro while another four Western immunoblot-negative mAbs also neutralise the virus. The utility of these mAbs for diagnostic development is demonstrated. Antibody from convalescent SARS patients, but not normal human serum, is also shown to specifically compete off binding of mAbs to whole SARS-CoV. These studies highlight the importance of using standardised assays and reagents. These mAbs will be useful for the development of diagnostic tests, studies of SARS-CoV pathogenesis and vaccine development.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0166-0934</s0>
</fA01>
<fA02 i1="01"><s0>JVMEDH</s0>
</fA02>
<fA03 i2="1"><s0>J. virol. methods</s0>
</fA03>
<fA05><s2>120</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>BERRY (Jody D.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>JONES (Steven)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>DREBOT (Michael A.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>ANDONOV (Anton)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>SABARA (Marta)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>YUAN (Xin Y.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>WEINGARTL (Hana)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>FERNANDO (Lisa)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>MARSZAL (Peter)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>GREN (Jason)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>NICOLAS (Brigitte)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>ANDONOVA (Maya)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>RANADA (Francesca)</s1>
</fA11>
<fA11 i1="14" i2="1"><s1>GUBBINS (Michael J.)</s1>
</fA11>
<fA11 i1="15" i2="1"><s1>BALL (T. Blake)</s1>
</fA11>
<fA11 i1="16" i2="1"><s1>KITCHING (Paul)</s1>
</fA11>
<fA11 i1="17" i2="1"><s1>LI (Yan)</s1>
</fA11>
<fA11 i1="18" i2="1"><s1>KABANI (Amin)</s1>
</fA11>
<fA11 i1="19" i2="1"><s1>PLUMMER (Frank)</s1>
</fA11>
<fA14 i1="01"><s1>National Centre for Foreign Animal Disease, CFIA</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>16 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Medical Microbiology, University of Manitoba</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>National Microbiology Laboratory Health Canada</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>17 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Immunology, University of Manitoba</s1>
<s2>Winnipeg</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA20><s1>87-96</s1>
</fA20>
<fA21><s1>2004</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>18295</s2>
<s5>354000120108570110</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2004 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>22 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>04-0407064</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of virological methods</s0>
</fA64>
<fA66 i1="01"><s0>NLD</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>There is a global need to elucidate protective antigens expressed by the SARS-coronavirus (SARS-CoV). Monoclonal antibody reagents that recognise specific antigens on SARS-CoV are needed urgently. In this report, the development and immunochemical characterisation of a panel of murine monoclonal antibodies (mAbs) against the SARS-CoV is presented, based upon their specificity, binding requirements, and biological activity. Initial screening by ELISA, using highly purified virus as the coating antigen, resulted in the selection of 103 mAbs to the SARS virus. Subsequent screening steps reduced this panel to seventeen IgG mAbs. A single mAb, F26G15, is specific for the nucleoprotein as seen in Western immunoblot while five other mAbs react with the Spike protein. Two of these Spike-specific mAbs demonstrate the ability to neutralise SARS-CoV in vitro while another four Western immunoblot-negative mAbs also neutralise the virus. The utility of these mAbs for diagnostic development is demonstrated. Antibody from convalescent SARS patients, but not normal human serum, is also shown to specifically compete off binding of mAbs to whole SARS-CoV. These studies highlight the importance of using standardised assays and reagents. These mAbs will be useful for the development of diagnostic tests, studies of SARS-CoV pathogenesis and vaccine development.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05C09</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Développement</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Development</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Desarrollo</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Anticorps monoclonal</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Monoclonal antibody</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Anticuerpo monoclonal</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Déterminant antigénique</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Antigenic determinant</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Determinante antigénico</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Immunochimie</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Immunochemistry</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Inmunoquímica</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Microbiologie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Microbiology</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Microbiología</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Méthode</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Method</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Método</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Virologie</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Virology</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Virología</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Virose</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Viral disease</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Virosis</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Infection</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Infection</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Infección</s0>
<s2>NM</s2>
</fC07>
<fN21><s1>229</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 04-0407064 INIST</NO>
<ET>Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus</ET>
<AU>BERRY (Jody D.); JONES (Steven); DREBOT (Michael A.); ANDONOV (Anton); SABARA (Marta); YUAN (Xin Y.); WEINGARTL (Hana); FERNANDO (Lisa); MARSZAL (Peter); GREN (Jason); NICOLAS (Brigitte); ANDONOVA (Maya); RANADA (Francesca); GUBBINS (Michael J.); BALL (T. Blake); KITCHING (Paul); LI (Yan); KABANI (Amin); PLUMMER (Frank)</AU>
<AF>National Centre for Foreign Animal Disease, CFIA/Winnipeg/Canada (1 aut., 5 aut., 6 aut., 7 aut., 9 aut., 10 aut., 11 aut., 13 aut., 16 aut.); Department of Medical Microbiology, University of Manitoba/Winnipeg/Canada (1 aut., 3 aut., 4 aut., 15 aut., 18 aut., 19 aut.); National Microbiology Laboratory Health Canada/Winnipeg/Canada (2 aut., 3 aut., 4 aut., 6 aut., 8 aut., 11 aut., 12 aut., 13 aut., 14 aut., 17 aut., 18 aut., 19 aut.); Department of Immunology, University of Manitoba/Winnipeg/Canada (2 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Journal of virological methods; ISSN 0166-0934; Coden JVMEDH; Pays-Bas; Da. 2004; Vol. 120; No. 1; Pp. 87-96; Bibl. 22 ref.</SO>
<LA>Anglais</LA>
<EA>There is a global need to elucidate protective antigens expressed by the SARS-coronavirus (SARS-CoV). Monoclonal antibody reagents that recognise specific antigens on SARS-CoV are needed urgently. In this report, the development and immunochemical characterisation of a panel of murine monoclonal antibodies (mAbs) against the SARS-CoV is presented, based upon their specificity, binding requirements, and biological activity. Initial screening by ELISA, using highly purified virus as the coating antigen, resulted in the selection of 103 mAbs to the SARS virus. Subsequent screening steps reduced this panel to seventeen IgG mAbs. A single mAb, F26G15, is specific for the nucleoprotein as seen in Western immunoblot while five other mAbs react with the Spike protein. Two of these Spike-specific mAbs demonstrate the ability to neutralise SARS-CoV in vitro while another four Western immunoblot-negative mAbs also neutralise the virus. The utility of these mAbs for diagnostic development is demonstrated. Antibody from convalescent SARS patients, but not normal human serum, is also shown to specifically compete off binding of mAbs to whole SARS-CoV. These studies highlight the importance of using standardised assays and reagents. These mAbs will be useful for the development of diagnostic tests, studies of SARS-CoV pathogenesis and vaccine development.</EA>
<CC>002A05C09</CC>
<FD>Coronavirus; Développement; Anticorps monoclonal; Déterminant antigénique; Immunochimie; Microbiologie; Méthode; Virologie; Syndrome respiratoire aigu sévère</FD>
<FG>Coronaviridae; Nidovirales; Virus; Virose; Infection</FG>
<ED>Coronavirus; Development; Monoclonal antibody; Antigenic determinant; Immunochemistry; Microbiology; Method; Virology; Severe acute respiratory syndrome</ED>
<EG>Coronaviridae; Nidovirales; Virus; Viral disease; Infection</EG>
<SD>Coronavirus; Desarrollo; Anticuerpo monoclonal; Determinante antigénico; Inmunoquímica; Microbiología; Método; Virología; Síndrome respiratorio agudo severo</SD>
<LO>INIST-18295.354000120108570110</LO>
<ID>04-0407064</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000843 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000843 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:04-0407064
   |texte=   Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus

Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri